Strong background in bone diseases, virology, neurosciences, nephrology
Holder of a Ph.D in Biochemistry, Cellular and Molecular Biology, I have been focused on the preclinical development of therapeutic molecules, the elucidation of the mechanisms of action of these molecules and the discovery of the mechanisms involved in human pathologies (osteoarthritis, genetic brain and kidney diseases).
In this context, beyond technical skills, I have developed soft skills which allowed me to carry out the missions I have been entrusted :
Management skills :
Supervision of CROs
Coordination of expert networks
Team supervision
Scientific project management
Communication skills :
Reporting
Written and oral presentation of data
Redaction of scientific projects and documents
Scientific skills :
Study design
Development of procedures
Bibliographic and technological survey
Project review
The development of therapeutic molecules is still topical and remains a public health challenge in which I still want to get involved as a preclinical R&D project manager.
Projects reporting to the CSO, partners and collaborators
Presentation and discussion of data at internal and international meetings
Scientific documents redaction
Writing of a scientific project for funds (BpiFrance-Deeptech
Propose and write a preclinical development plan
Scientific skills :
Identify project objectives
From hit to lead (RNA)
Study plans definition and design
Design and development of GLP experimental procedures
Analyses and interpretation of results
Team working and troubleshooting abilities
Literature and technologic survey
Detailed Description
Achievements : Identification of 20 candidate antiviral molecules (Zika, Dengue, Chikungunya) Design, follow-up and completion of 2 in vitro efficacy studies, 2 in vivo efficacy studies Management of an international network of 10 CROs Review of 10 CRO study reports 1 grant obtained (€1.2 M; Bpifrance Deeptech)
Company Description
Meletios Therapeutics’ aim is to fulfill the urgent and large unmet medical need for broad spectrum treatments against current and emerging viral infections.
This French biotech company was created in April 2020 by a team of high level scientists and experienced biotech managers.
One of our first drug candidate has confirmed its broad-spectrum potential in in vitro and in vivo models on the coronavirus family and influenza H1N1, demonstrating a dual antiviral and anti-inflammatory activity. This molecule will now be developed and tested in order to meet regulatory requirements and enter clinical phase II.
Several drug candidates from Meletios portfolio are currently being tested both in vitro and in vivo and will expand our range of antiviral molecules on different RNA viruses.
Meletios Therapeutics’ goal is to become a global leader in the fight against emerging viral infections by developing innovative broad-spectrum therapeutic solutions.
